Výsledky vyhledávání - "Alison Potts-Bleakman"

Akademický článek

Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults

Autor: Marla C. Dubinsky, Peter M. Irving, Remo Panaccione, April N. Naegeli, Alison Potts-Bleakman, Vipin Arora, Mingyang Shan, Simon Travis

Publikováno v: Journal of Patient-Reported Outcomes, Vol 6, Iss 1, Pp 1-11 (2022)

Abstract Background Bowel urgency, the sudden or immediate need to have a bowel movement, is a common, bothersome and disruptive symptom of ulcerative colitis (UC). UC treatment goals include control of urgency; however, it is not consistently assess

Externí odkaz: https://doaj.org/article/c7fd842e48c741bdbd35587dbd19052e

Zobrazit plný text záznamu

Akademický článek

Patient perception of bowel urgency and remission in moderately to severely active Crohn’s disease or ulcerative colitis: a qualitative study

Autor: Theresa Hunter Gibble, Larissa Stassek, Gale Harding, Marissa Stefan, Tsion Fikre, Alison Potts Bleakman, Richard Moses, Marla Dubinsky

Publikováno v: Journal of Patient-Reported Outcomes, Vol 8, Iss 1, Pp 1-13 (2024)

Abstract Background Bowel urgency, the sudden and immediate need to have a bowel movement, is common in patients with ulcerative colitis (UC) and Crohn’s disease (CD). While its impact in UC is well established, less is known about its importance i

Externí odkaz: https://doaj.org/article/7ecddf7842ce422890918b1df71f5a89

Zobrazit plný text záznamu

Akademický článek

Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial

Autor: Lyn Guenther, Alison Potts Bleakman, Jamie Weisman, Yves Poulin, Lynda Spelman, Russel Burge, Janelle Erickson, Kristin Todd, Clinton C. Bertram, Caitriona Ryan

Publikováno v: Acta Dermato-Venereologica, Vol 100, Iss 1, p adv00006 (2020)

Ixekizumab was efficacious in treating moderate-to-severe genital psoriasis over 12 weeks. We evaluated the long-term efficacy and safety of ixekizumab for up to 52 weeks. Patients were randomized to 80 mg ixekizumab every 2 weeks or to placebo throu

Externí odkaz: https://doaj.org/article/235ce9220775439fa1908ae152d943a9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání